Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT ® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the ...

Dortmund, Germany, 26 October 2012 – Successful treatment of respiratory diseases also depends on how much of the active substance enters the patient's lung. Boehringer Ingelheim's Respimat® Soft ...

Madison, Wisconsin-based Propeller Health has secured two new FDA clearances for new sensors that are designed to work with two particular inhalers on the market: the Diskus inhaler from ...

Qualcomm Life and Boehringer Ingelheim have announced that they will work together to develop the next generation of Boehringer's Respimat connected inhaler. Propeller Health, which developed the ...

Add Yahoo as a preferred source to see more of our stories on Google. Are Americans paying nearly $500 for an inhaler that would cost just $7 overseas? U.S. Sen. Tammy Baldwin, D-Wis., says there is a ...

The U.S. Food and Drug Administration approved Striverdi Respimat (olodaterol), an inhalation spray drug aimed at treating patients with chronic obstructive pulmonary disease. Striverdi Respimat is a ...

March 7 (Reuters) - Boehringer Ingelheim will cap out-of-pocket costs for the company's inhaler products for a chronic lung disease and asthma at $35 per month starting June 1, the German drugmaker ...

An international study led by a Johns Hopkins pulmonary expert finds that the drug tiotropium (marketed as the Spiriva brand), can be delivered safely and effectively to people with chronic ...

Statement: “Big drug companies charge as little as $7 for an inhaler overseas and nearly $500 for the exact same one here in the US.” Are Americans paying nearly $500 for an inhaler that would cost ...

Are Americans paying nearly $500 for an inhaler that would cost just $7 overseas? U.S. Sen. Tammy Baldwin, D-Wis., says there is a vast difference in the cost of prescriptions in the United States and ...

Experts say a key reason why inhaler prices remain so high in the U.S. is that there is very little generic competition. The Senate committee, in a letter to the pharma CEOs, cited an online global ...